

# Novartis AG (ADR)

02:03 20 Oct 2016

## Cerulean Pharma shares soar after news of Novartis tie-up

Shares in cancer drug discovery firm Cerulean Pharma Inc (NASDAQ:CERU) soared after it announced that it had teamed up with pharmaceutical giant Novartis (NYSE:NVS) in a discovery and development deal.

Novartis is buying into the promise of Cerulean's nanoparticle drug conjugates (NDCs) and is making an upfront payment of US\$5mln as well as funding the first five candidates.

Long term investor Aspire Capital has also committed to ploughing US\$20mln into the struggling microcap.

Under the terms of the deal, Cerulean's Dynamic Tumour Targeting technology will be combined with Novartis' compounds against up to five targets.

Cerulean is to create the NDCs, with Novartis being responsible for further development and the commercialisation of the products.

"Novartis is widely recognised as one off the world leaders in drug development," said Cerulean President Christophe Guiffre.

"This collaboration is further validation of our powerful technology platform, and we are excited that Novartis is including NDCs in its drug discovery and development efforts."

In addition to the upfront payment, Cerulean is also eligible for cash boosts if, or when, it hits certain preclinical, clinical, regulatory and sales milestones for each target.

Cerulean has endured a difficult time since it listed on NASDAQ back in 2014.

The stock hit a high of US\$10 last year, but fell below a buck this summer after its lead candidate CRLX101 failed in a combination trial to beat treatment of care in the treatment of renal cell carcinoma.


The company then pretty much slashed its workforce in half following the failure.

Shares in Cerulean climbed 53% to US\$1.04, while Novartis dipped slightly to trade at US\$76.

**Price:** 89.76

**Market Cap:** \$204.16 billion

### 1 Year Share Price Graph



### Share Information

**Code:** NVS

**Listing:** NYSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	99.82	69.31

**Sector:** Pharma & Biotech

**Website:** [www.novartis.com](http://www.novartis.com)

### Company Synopsis:

*Novartis provides healthcare solutions that address the evolving needs of patients and societies.*

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.